GlobeNewsWire
14 Jun 2026, 14:00 UTC · 3h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
Lorundrostat is currently under FDA review with a PDUFA target date of December 22, 2026. — The PDUFA date is the primary catalyst for the stock as it represents the imminent binary outcome of regulatory approval.
+0.60Proteomic analysis showed lorundrostat significantly reduced 6 of 11 causal risk biomarkers for heart failure, including NT-proBNP. — Positive biomarker data suggests a broader therapeutic application and potential for future label expansions into heart failure.
+0.40Data from Phase 3 Launch-HTN and Phase 2b Advance-HTN trials suggest the drug favorably modulates pathways reducing harmful fibrosis. — Provides biological plausibility for the drug's efficacy, increasing investor confidence in the drug's mechanism of action.
+0.30Which stocks this story touches
Continue reading
6 related stories
Top 1 mover · tap to explore
The company presented positive late-breaking data showing lorundrostat is associated with significant reductions in heart failure risk biomarkers.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
GlobeNewsWire
8h ago
